Cancer
Memorial Sloan Kettering Cancer Center officials violated conflict of interest policies
April 5, 2019Medical Communications, Research and Development Cancer, Memorial Sloan Kettering Cancer Center, oncology, research
Top officials at the Memorial Sloan Kettering Cancer Center repeatedly violated policies on financial conflicts of interest, according to details …
European approval for Pfizer’s Vizimpro in first-line non-small cell lung cancer
April 4, 2019Sales and Marketing Cancer, Europe, Pfizer, Vizimpro, lung cancer, non small cell lung cancer, non-small cell lung cancer, pharma
The European Commission has awarded marketing approval to Pfizer’s tyrosine kinase inhibitor (TKI) Vizimpro (dacomitinib), it has emerged, as a …
Clovis Oncology’s Rubraca shows promise in multiple pancreatic tumour mutations, interim data show
April 3, 2019Research and Development Cancer, Clovis Oncology, Pancreatic cancer, Rubraca, oncology, pharma
At the 2019 American Association for Cancer Research (AACR) Annual Meeting in Atlanta, Clovis Oncology took the opportunity to present …
NICE recommends Eli Lilly’s Verzenio in combination with Fulvestrant for breast cancer
April 2, 2019Manufacturing and Production CDF, Cancer, NICE, breast cancer, britain, oncology
Britain’s cost effectiveness body, the National Institute for Health and Care Excellence (NICE), has recommended Eli Lilly’s Verzenio (abemaciclib) in …
Artios Pharma name experienced oncologist as company’s new CMO
April 1, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Artios Pharma, CMO, Cancer, DDR, oncology
British biotech Artios Pharma have appointed experienced oncologist Dr Ian Smith, as the company’s new Chief Medical Officer (CMO). Dr …
Indian authorities say J&J’s baby shampoo contains ‘harmful ingredients’
April 1, 2019Sales and Marketing Cancer, India, J&J, JJ, Johnson & Johnson, Rajasthan, baby shampoo, formaldehyde
Indian authorities in the state of Rajasthan have said that samples taken from Johnson & Johnson’s baby shampoo contained ‘harmful …
Roche’s Tecentriq combo shows promise in first-line triple-negative breast cancer
April 1, 2019Research and Development, Sales and Marketing Cancer, Roche, breast cancer, pharma, tecentriq
Roche has revealed new Phase 1b data on a new Tecentriq combo, showing early promise in the first-line treatment of …
AstraZeneca and Daiichi Sankyo partner up for $6.9 billion cancer collaboration
March 29, 2019Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Cancer, Daiichi Sankyo, pharma
AstraZeneca and Daiichi Sankyo have announced a new collaboration agreement to the tune of potentially $6.9 billion which will see …
AstraZeneca’s Imfinzi to be made available via Cancer Drugs Fund in England
March 28, 2019Sales and Marketing AstraZeneca, Cancer, Imfinzi, NHS, NICE, UK, lung cancer
AstraZeneca’s PD-L1 inhibitor Imfinzi (durvalumab) will now be made available to English lung cancer patients on the NHS via the …
NICE recommend Takeda’s lymphoma treatment Adcetris
March 25, 2019Sales and Marketing Cancer, NICE, Takeda, UK, lymphoma, oncology, recommendation
Britain’s cost effectiveness body has recommended Takeda’s Adcetris (brentuximab vedotin) for adult patients with CD-30 positive advanced cutaneous T-cell lymphoma …
Breast cancer mortality rates fall faster in Britain than elsewhere in Europe
March 19, 2019Manufacturing and Production, Research and Development Cancer, EU, Europe, France, Italy, Poland, UK, breast cancer, german, oncology
Death rates from breast cancer are falling faster in Britain than in any of the other six most populous countries …
Shortage of cancer doctors puts NHS patients at risk
March 19, 2019Manufacturing and Production, Research and Development Cancer, NHS, oncologists, radiology, shortfall, staff
A shortage of cancer doctors is putting patients at risk, according to a new report from the Royal College of …
MSD’s Keytruda/chemo combo nabs EU approval in first-line metastatic squamous lung cancer
March 15, 2019Medical Communications, Sales and Marketing Cancer, MSD, NSCLC, keytruda, lung cancer, pharma
MSD’s anti-PD-L1 therapy Keytruda (pembrolizumab) has been awarded marketing authorisation in Europe for the first-line treatment of adult patients with …
Lilly’s Cyramza hits Phase 3 endpoint in first-line metastatic lung cancer treatment
March 13, 2019Research and Development Cancer, Eli Lilly, cyramza, lung cancer, pharma
Eli Lilly’s vascular endothelial growth factor (VEGF) Receptor 2 antagonist Cyramza (ramucirumab) has succeeded in hitting its primary endpoint at …
FDA approves first diagnostic tool to target triple-negative breast cancer patients
March 11, 2019Sales and Marketing Cancer, Roche, Ventana, breast cancer, pharma
Roche’s Ventana PD-L1 Assay has become the first FDA-approved companion diagnostic for the identification of patients with triple-negative breast cancer …
Latest content
Five Facts about cardiovascular disease
